Jun 26
|
General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls
|
Jun 25
|
No Ad Comm ‘not necessarily positive’ for Capricor, says Roth Capital
|
Jun 25
|
Capricor’s deramiocel moves ahead without AdCom, says H.C. Wainwright
|
Jun 24
|
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
|
Jun 21
|
Capricor Therapeutics announces four-year data from HOPE-2 OLE study
|
Jun 20
|
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
|
Jun 17
|
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
|
Jun 12
|
Capricor says FDA inspection brought Form 483 with several observations
|
Jun 11
|
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
|
May 22
|
Exploring 3 High Growth Tech Stocks In The US Market
|
May 7
|
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
|
May 6
|
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
|
Apr 17
|
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?
|
Mar 27
|
High Growth Tech Stocks In The US Market With Promising Potential
|
Mar 11
|
Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
|
Mar 10
|
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
|
Feb 17
|
High Growth Tech Stocks In The United States To Watch
|
Feb 10
|
Capricor Therapeutics to Participate in Upcoming Investor Conferences
|
Jan 3
|
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
|
Jan 2
|
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
|